Medicine record
Generic semaglutide in Canada
Every generic semaglutide product authorized in Canada, its status, what Ontario pays and the recalls so far.
Generic semaglutide arrived in Canada in 2026. Most of the generics copy Ozempic and are for type 2 diabetes. One, Sevmia, copies Wegovy and is for weight management. This page lists each one, what it is for, whether it is on pharmacy shelves, what Ontario's public plan pays, and the recalls so far.
A generic being approved does not mean a pharmacy has it, and does not mean a plan pays for it. Nothing here is a dose or a recommendation; switching products is a decision for the prescriber and pharmacist.
The generics, one by one
| Product | Company | Copies | Approved for | Status in Health Canada's database |
|---|---|---|---|---|
| Apo-Semaglutide Injection | Apotex | Ozempic | Type 2 diabetes in adults R21-C453 | Marketed since 14 May 2026 |
| Semaglutide Injection | Dr. Reddy's | Ozempic | Type 2 diabetes in adults R21-C454 | Marketed since 6 May 2026 |
| Aspen-Semaglutide | Aspen | Ozempic | Type 2 diabetes in adults R21-C455 | Approved 17 July 2026, not marketed |
| Semaglutide Injection | Aspen | Ozempic | Type 2 diabetes in adults R21-C456 | Approved 25 August 2026, not marketed |
| Semaglutide | Sandoz | Ozempic | Type 2 diabetes | Approved 16 September 2026, no launch date given R43-C12 |
| Sevmia | Apotex | Wegovy | Weight management in adults and teens 12 and up, and heart attack risk reduction R21-C432 R21-C444 | Approved 29 June 2026, not marketed |
Health Canada said in June 2026 that six more generic semaglutide submissions were under review R43-C13, so this list will grow.
Sevmia, the Wegovy generic
Sevmia comes as one pen that gives 1 mg doses only. The monograph says other products are needed for the other doses A-C02, so it cannot cover a whole treatment course on its own. Its status in Health Canada's database is Approved, not Marketed, so it is not on pharmacy shelves yet.
Not generics: Plosbrio and Poviztra
Plosbrio and Poviztra are new product names from Novo Nordisk for the same medicines as Ozempic and Wegovy. They are not generics and are approved but not marketed R21-C457 R21-C458.
What public plans pay
Ontario is the clearest example. For the Ozempic 2 mg pen, Ontario Drug Benefit lists Ozempic at $227.94 but pays $78.141, the generic price, because the products are interchangeable R21-C497. Apo-Semaglutide is listed at $78.141 R21-C496. Sevmia is listed at $325.048 per pen but is off formulary, so the Ontario plan pays nothing for it R21-C503.
The provincial plans reviewed on this site still cover semaglutide only for type 2 diabetes, under criteria; see the coverage record for each province. Private plans set their own rules; their forms are on the prior authorization forms page.
Recalls so far
All four recalls below are Type II. They do not change the products' status in Health Canada's database.
| Date | Product | Problem |
|---|---|---|
| 11 August 2026 | Semaglutide Injection (Dr. Reddy's) | Wrong pen in the package, one lot R43-C14 |
| August 2026 | Semaglutide Injection (Dr. Reddy's) | Impurity out of specification, several lots R21-C423 |
| 27 August 2026 | Apo-Semaglutide 2 mg pen | Dose display incorrect R43-C15 |
| 23 September 2026 | Apo-Semaglutide 4 mg pen | Dose display incorrect, one lot R43-C16 |
If you have a pen from a recalled lot, the recall notice explains what to do; your pharmacist can check the lot number.
More about semaglutide
- Semaglutide in Canada: every product, presentation and status.
- Wegovy, Ozempic, Mounjaro and Zepbound compared.
- Who can be prescribed Wegovy or Zepbound.
Common questions
Is there a generic Wegovy in Canada?
Yes. Sevmia from Apotex was approved on 29 June 2026 for weight management, but it is not marketed yet and comes only as a 1 mg pen A-C02 R21-C432.
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
| Claim | What the source says | Source | Source date | Accessed | Label |
|---|---|---|---|---|---|
| R21-C453 | Adult type 2 diabetes glycemic control, specified combinations; no pediatric indication. Prefilled multidose pens: 2 mg/3 mL delivering 0.25/0.5 mg, or 4 mg/3 mL delivering 1 mg. | pdf.hres.ca/dpd_pm/00084514.PDF | 2026-05-01 | 2026-09-17 | regulator-confirmed |
| R21-C454 | Adult type 2 diabetes glycemic control, specified combinations; no pediatric indication. 1.34 mg/mL pens: 2 mg/1.5 mL delivering 0.25/0.5 mg; 4 mg/3 mL delivering 1 mg. | pdf.hres.ca/dpd_pm/00084444.PDF | 2026-04-28 | 2026-09-17 | regulator-confirmed |
| R21-C455 | Adult type 2 diabetes glycemic control; no pediatric indication. 1.34 mg/mL multidose pens: 2 mg/1.5 mL (0.25/0.5 mg delivered) and 4 mg/3 mL (1 mg delivered). | pdf.hres.ca/dpd_pm/00085376.PDF | 2026-07-17 | 2026-09-17 | regulator-confirmed |
| R21-C456 | Adult type 2 diabetes glycemic control; no pediatric indication. 1.34 mg/mL multidose pens: 2 mg/1.5 mL (0.25/0.5 mg delivered), 4 mg/3 mL (1 mg delivered). | pdf.hres.ca/dpd_pm/00085867.PDF | 2026-08-25 | 2026-09-17 | regulator-confirmed |
| R43-C12 | Health Canada authorized Sandoz generic semaglutide (DINs 02571501 and 02571528) on 2026-09-16; Sandoz gave no launch date. | webdisclosure.com/press-release/sandoz-receives-regulator... | 2026-09-18 | 2026-10-04 | regulator-confirmed |
| R21-C432 | Weight management: adults BMI ≥30, or ≥27 plus comorbidity; ages 12 to <18 with BMI ≥95th percentile, >60 kg and inadequate diet/activity response. Adult nonfatal-MI risk reduction: established CVD and BMI ≥27. | pdf.hres.ca/dpd_pm/00085157.PDF | 2026-06-29 | 2026-09-17 | regulator-confirmed |
| R21-C444 | NOC 37782 is an abbreviated new drug submission, with Wegovy as Canadian reference product; no NOC conditions. | health-products.canada.ca/noc-ac/nocInfo?no=37782 | 2026-06-29 | 2026-09-17 | regulator-confirmed |
| R43-C13 | Health Canada said Sevmia was the third generic semaglutide it had approved and that six additional generic semaglutide submissions were under review. | canada.ca/en/health-canada/news/2026/06/canada-approves-f... | 2026-06-29 | 2026-10-04 | regulator-confirmed |
| A-C02 source 1 of 2 | Sevmia first generic weight-management semaglutide authorized June 29 | canada.ca/en/health-canada/news/2026/06/canada-approves-f... | 2026-06-29 | 2026-09-16 | regulator-confirmed |
| A-C02 source 2 of 2 | Sevmia 02569582 supplies 1 mg weekly presentation; other doses require other products | pdf.hres.ca/dpd_pm/00085157.PDF | 2026-06-29 | 2026-09-16 | regulator-confirmed |
| R21-C457 | Adults: type 2 diabetes glycemic control; MACE reduction with established CVD and/or CKD; sustained eGFR-decline, end-stage-kidney-disease and CV-death risk reduction with CKD. No pediatric indication. Multidose pens deliver 0.25/0.5, 1 or 2 mg. | pdf.hres.ca/dpd_pm/00085721.PDF | 2026-08-06 | 2026-09-17 | regulator-confirmed |
| R21-C458 | Weight management: adults BMI ≥30 or ≥27 with comorbidity; ages 12 to <18 with BMI ≥95th percentile, >60 kg, inadequate diet/activity response. Adult nonfatal-MI reduction with established CVD/BMI ≥27. Single/multidose pens deliver 0.25/0.5/1/1.7/2.4 mg. No MASH indication shown. | pdf.hres.ca/dpd_pm/00082882.PDF | 2025-12-22 | 2026-09-17 | regulator-confirmed |
| R21-C497 | Ontario DIN 02540258 Ozempic 0.68 mg/mL, 3 mL pen pack: Limited Use 667; DBP or Unit Price 227.9400 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C496 | Ontario DIN 02568020 Apo-Semaglutide Injection 0.68 mg/mL, 3 mL pen pack: Limited Use 667; DBP or Unit Price 78.1410 CAD; MOH pays 78.1410; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R21-C503 | Ontario DIN 02569582 Sevmia 4 mg/3 mL pen: Off-Formulary Interchangeable; LU No; not General Benefit; DBP or Unit Price 325.0480 CAD; MOH pays N/A; interchangeability Yes. | formulary.health.gov.on.ca/formulary/results.xhtml?q=sema... | edition effective 2026-08-31; last updated 02/09/2026; version 2.17 | 2026-09-17 | regulator-confirmed |
| R43-C14 | Recall RA-82477: Semaglutide Injection (Dr. Reddy's), incorrect pen in package, lot 7000544C, Type II. | recalls-rappels.canada.ca/en/alert-recall/semaglutide-inj... | 2026-08-11 | 2026-10-04 | regulator-confirmed |
| R21-C423 | Recall RA-82537 includes both DINs: 02567806 lots 7000544/7000545/7000546; 02567814 lots 7000542/7000543/7000624/7000628/7000629. DPD still says Marketed. The notice reports an impurity outside specifications; Type II retail recall. | recalls-rappels.canada.ca/en/alert-recall/semaglutide-inj... | Updated 2026-08-26; original published 2026-08-27 | 2026-09-17 | regulator-confirmed |
| R43-C15 | Recall RA-82536: Apo-Semaglutide Injection 2 mg pen, incorrect dose display, Type II. | recalls-rappels.canada.ca/en/alert-recall/apo-semaglutide... | 2026-08-27 | 2026-10-04 | regulator-confirmed |
| R43-C16 | Recall RA-82679: Apo-Semaglutide Injection 4 mg pen, incorrect dose display, lot 7000636A, Type II. | recalls-rappels.canada.ca/en/alert-recall/apo-semaglutide... | 2026-09-23 | 2026-10-04 | regulator-confirmed |